Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
NCT ID: NCT03560804
Last Updated: 2018-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2014-11-10
2017-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
The other basic aim of the study is to determine whether there is a difference (\>6mmHg) between the two drugs regarding the reduction of the mean 24hour blood pressure and the effect of them on the hemodynamic parameters.
The hemodynamic parameters that will be measured by applanation tonometry are augmentation index, central blood pressure and pulse wave velocity.
The hemodynamic parameters that will be measured by impedance cardiography are cardiac index, thoracic fluid content index, systemic vascular resistance index and others.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy
NCT00295542
Non-invasive Haemodynamic Assessment in Hypertension
NCT01996085
Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension
NCT00971165
Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients
NCT00135551
Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension
NCT01850901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Olmesartan
ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Olmesartan
Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
Chlorthalidone
Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
Chlorthalidone
Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olmesartan
Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
Chlorthalidone
Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the ESH/ESC guidelines 2013
* The patient has signed the concent form
Exclusion Criteria
* 3rd grade of Arterial Hypertension
* Chronic renal failure
* Diabetes Mellitus
* Sleep apnea syndrome
* Chronic or acute inflammatory diseases
* Stroke, myocardial infarction, angina pectoris in the past 6 months
* Heart failure
* Liver disease
* Neoplasms
* Pregnancy
* Valvular Heart disease
* Heigt \< 120cm or \> 230cm, Weight \<30kg or \>155kg
* Heart Arrhytmias
* Artificial cardiac pacemaker
* Hemodymanic unstable patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AHEPA University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria Pikilidou, MD, MSc, PhD
Post-doctoral researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zebekakis Pantelis, Professor
Role: PRINCIPAL_INVESTIGATOR
Hypertension Excellence Center, 1st Department of Internal Medicine, AHEPA University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hypertension Excellence Center, AHEPA University Hospital
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.